Showing results (211-220 of 280) with videos related to
Sort By:
Pageof 28
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemiasJudith E Karp, Brian M Thomas, Jacqueline M Greer, et al.Blood Advances|August 8, 2023
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapiesEdward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.Blood|June 24, 2009
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesTamer E Fandy, James G Herman, Patrick Kerns, et al.Pageof 28